on ORPHAN SYNERGY EUROPE-PHARMA (EPA:OSE)
OSE Immunotherapeutics Updates on Legal Proceedings
On July 2, 2025, OSE Immunotherapeutics SA announced that the Nantes Commercial Court has rejected a group of shareholders' motions. These motions aimed to retract an earlier order that permitted the adjournment of OSE's annual general meeting, initially authorized on June 10, 2025.
Further legal action has been taken by OSE Immunotherapeutics against the same shareholder group. This is in response to concerns about the declaration of concerted shareholder action. A hearing is scheduled for September 8, 2025. The company aims to ensure transparency ahead of the upcoming annual general meeting.
Presently, OSE Immunotherapeutics plans to hold its annual shareholders' meeting on September 30, 2025, pending further legal developments.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all ORPHAN SYNERGY EUROPE-PHARMA news